Several novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern have emerged since the inception of the pandemic. These variants often displaying enhanced infectiousness and virulence compared with wild-type strain. Whole genome sequencing is currently the gold standard in the identification and monitoring of these lineages. However, the set-up costs and operational requirements of facilities capable of processing such large sample volumes have been prohibitive, exceeding what is clinically actionable for most patients.
